Compare XFOR & KEYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XFOR | KEYY |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 45 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.3M | 341.0M |
| IPO Year | N/A | 2026 |
| Metric | XFOR | KEYY |
|---|---|---|
| Price | $4.56 | $9.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 571.4K | 11.1K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $9.84 |
| 52 Week High | $4.83 | $9.90 |
| Indicator | XFOR | KEYY |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 46.02 |
| Support Level | $3.54 | $9.84 |
| Resistance Level | $4.51 | $9.88 |
| Average True Range (ATR) | 0.22 | 0.01 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 79.22 | 25.00 |
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Keystone Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.